Thymoma

He had tried superpotent topical corticosteroids and oral prednisolone, as well as emollients, none of which had improved his symptoms...Tralokinumab was trialled for 12 weeks, as this has a single therapeutic target (interleukin-13), but unfortunately there was no improvement. Following discussion with the immunologists, he was commenced on upadacitinib as this was felt to have a more targeted immunosuppressive effect above agents such as methotrexate and dupilumab. We await his next follow-up appointment to assess response. This case highlights the complexity of treating an immunocompromised individual with immunosuppressive agents, when the cause of their immunosuppression is unknown.

This preliminary study demonstrates the feasibility of establishing an animal model for thymoma and myasthenia gravis (MG) pathogenesis research by transplanting human thymoma tissues into BALB/c nude mice. Nevertheless, several issues and challenges must be resolved and investigated in future research.

These findings delineate a distinct systemic immune signature in TETs, characterized by IL-18 upregulation and altered ILC1 dynamics, with potential implications for immune regulation and autoimmunity. Circulating ILC profiling combined with IL-18 measurement may represent a promising approach for patient stratification, disease monitoring, and the development of novel immunomodulatory strategies in TETs.

This case highlights the importance of early immunologic assessment in patients with atypical or recurrent viral infections post-thymectomy. Prompt recognition of GS and initiation of IVIG therapy can be critical to achieving favorable outcomes.

© 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland

Specifically, stromal CD20+ TIIC density was independently associated with prolonged DFS(HR=4.74, 95% CI(1.673-13.434), P=0.003) and OS (HR=5.086, 95% CI(1.391-18.594), P=0.014), whereas elevated CD204+ TIIC infiltration correlated with reduced DFS(HR=0.154, 95% CI(0.043-0.547), P=0.004) and OS(HR=0.169, 95% CI(0.056-0.607), P=0.002). These findings suggest that targeting M2 macrophage-driven immunosuppression may enhance therapeutic efficacy in TETs.

Carfilzomib synergized with BCL2 family protein inhibitors (navitoclax or AZD5991), suggesting that drug combinations could be used to reduce the dose of each drug to minimize toxicity. Notably, thymic carcinomas differed from squamous cell carcinomas in other organs by higher levels of β5i (PSMB8) and constitutive proteasome β5 (PSMB5). We hypothesize that TC (and probably many TH) are uniquely suited for treatment with proteasome inhibitors alone or in combination with selective BH3 mimetics.

P2, N=20, Recruiting, The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting --> Recruiting

We present a surgical case of an extremely rare asynchronous, isolated thymic metastasis that occurred over 10 years after initial breast cancer surgery. This case underscores the importance of considering thymic metastasis in the differential diagnosis of anterior mediastinal tumors in patients with a remote history of breast cancer.

Tumors with a CD20 score of 3 demonstrated a tendency towards higher SPT24 or SP141 expression. Different expressions by TTF-1 clone may be diagnostic challenges in type A/AB thymomas, and pathologists should be aware of aberrant TTF-1 expression using SPT24 and SP141 clone in thymomas.

Evaluation revealed hypogammaglobulinemia along with CD4+ T-cell and B-cell lymphopenia, thus indicating Good's syndrome. Our case highlights the importance of including Good's syndrome in the differential diagnosis of HIV-negative, acquired, adult immunodeficiency and elucidates the general principles of management of this rare clinical entity.

She received granulocyte colony-stimulating factor (GCSF), thrombopoietin (TPO) mimetic, and immunosuppressive therapy with prednisone prior to primary cytoreductive surgery to no apparent gross residual disease...She was treated with anti-thymocyte globulin (ATG) and cyclosporine and subsequently received adjuvant chemotherapy with weekly cisplatin and subsequent addition of weekly paclitaxel, resulting in reduction in her serum Cancer Antigen-125 (CA-125) and no radiographic evidence of disease. Despite initial response, her clinical deterioration and her decision to forego further cancer- or aplastic anemia-directed therapy resulted in transition to home hospice care, and she was discharged 119 days after admission. This case report highlights the importance of multi-disciplinary collaboration to manage the medical complexities of paraneoplastic aplastic anemia secondary to a gynecologic malignancy.